MX2024012368A - Terapia combinada para el tratamiento del cancer - Google Patents

Terapia combinada para el tratamiento del cancer

Info

Publication number
MX2024012368A
MX2024012368A MX2024012368A MX2024012368A MX2024012368A MX 2024012368 A MX2024012368 A MX 2024012368A MX 2024012368 A MX2024012368 A MX 2024012368A MX 2024012368 A MX2024012368 A MX 2024012368A MX 2024012368 A MX2024012368 A MX 2024012368A
Authority
MX
Mexico
Prior art keywords
combination therapy
treating cancer
combination
azd5305
darolutamide
Prior art date
Application number
MX2024012368A
Other languages
English (en)
Spanish (es)
Inventor
Sabina Chiara Cosulich
BROWN Jessica S
Albertella Mark R
Elisabetta Leo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2024012368A publication Critical patent/MX2024012368A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024012368A 2022-04-07 2024-10-04 Terapia combinada para el tratamiento del cancer MX2024012368A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362612P 2022-04-07 2022-04-07
PCT/EP2023/059126 WO2023194528A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
MX2024012368A true MX2024012368A (es) 2024-11-08

Family

ID=86185292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012368A MX2024012368A (es) 2022-04-07 2024-10-04 Terapia combinada para el tratamiento del cancer

Country Status (11)

Country Link
US (1) US20250235448A1 (https=)
EP (1) EP4504180A1 (https=)
JP (1) JP2025511401A (https=)
KR (1) KR20240170956A (https=)
CN (1) CN118973572A (https=)
AU (1) AU2023248685A1 (https=)
CA (1) CA3254948A1 (https=)
IL (1) IL316016A (https=)
MX (1) MX2024012368A (https=)
TW (1) TW202404593A (https=)
WO (1) WO2023194528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026021478A1 (zh) * 2024-07-23 2026-01-29 江苏恒瑞医药股份有限公司 Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
AU2023248685A1 (en) 2024-11-14
CN118973572A (zh) 2024-11-15
IL316016A (en) 2024-11-01
TW202404593A (zh) 2024-02-01
US20250235448A1 (en) 2025-07-24
EP4504180A1 (en) 2025-02-12
JP2025511401A (ja) 2025-04-15
KR20240170956A (ko) 2024-12-05
CA3254948A1 (en) 2023-10-12
WO2023194528A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
MX2023012515A (es) Tratamiento del cancer con un inhibidor de raf.
MX2022002977A (es) Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
ZA201907225B (en) Treatment of her2 positive cancers
BR112018071023A2 (pt) combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose
MX2020009773A (es) Terapia de combinacion.
CR20170085A (es) Terapia adjuntiva con 25-hidroxi vitamina d
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
CL2024002772A1 (es) Compuestos de urea triciclicos como inhibidores de jak2 v617f.
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
MX2020001727A (es) Terapia de combinacion.
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
MX2022001450A (es) Metodo de tratamiento del cancer.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.